ArticleOncology letters2017
Silencing of semaphorin 3C suppresses cell proliferation and migration in MCF-7 breast cancer cells.
Article in Oncology letters, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 17 citations in OpenAlex.
- H2BE113K mutation promotes breast cancer metastasis through modulating chromatin dynamics.Science advances · 2026Article
- A LINE-1 retrotransposon promotes SEMA3C expression as a cis-regulatory enhancer to sustain breast cancer stem cell survival.Science China. Life sciences · 2026Article
- Sympathetic nerve-fibroblast crosstalk drives nerve injury, fibroblast activation, and matrix remodeling in pancreatic cancer.JCI insight · 2026Article
- HOXA5 is a key regulator of class 3 semaphorins expression in the synovium of rheumatoid arthritis patients.Rheumatology (Oxford, England) · 2023Article
- Article
- A comprehensive review of tumor proliferative and suppressive role of semaphorins and therapeutic approaches.Biophysical reviews · 2020Review
- Characterization of Class-3 Semaphorin Receptors, Neuropilins and Plexins, as Therapeutic Targets in a Pan-Cancer Study.Cancers · 2020Article
- A pan-cancer study of class-3 semaphorins as therapeutic targets in cancer.BMC medical genomics · 2020Article
- Semaphorin 3C as a Therapeutic Target in Prostate and Other Cancers.International journal of molecular sciences · 2019Review
- Class-3 Semaphorins and Their Receptors: Potent Multifunctional Modulators of Tumor Progression.International journal of molecular sciences · 2019Review
- SEMA3C Promotes Cervical Cancer Growth and Is Associated With Poor Prognosis.Frontiers in oncology · 2019Article
- Effects of Notch signalling on the expression of SEMA3C, HMGA2, CXCL14, CXCR7, and CCL20 in breast cancer.Turkish journal of biology = Turk biyoloji dergisi · 2019Article
- Importance of the putative furin recognition site 742RNRR745 for antiangiogenic Sema3C activity in vitro.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2018Article
- Semaphorin 3C and Its Receptors in Cancer and Cancer Stem-Like Cells.Biomedicines · 2018Review
- Impact of semaphorin expression on prognostic characteristics in breast cancer.Breast cancer (Dove Medical Press) · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Previous studies have suggested that semaphorin 3C (SEMA3C) is involved in the tumorigenesis and metastasis of a number of types of cancer. The aim of the present study was to investigate the role of SEMA3C in the proliferation and migration of MCF-7 breast cancer cells. Small interfering (si)RNA sequences targeting SEMA3C were constructed and transfected into MCF-7 cells in order to silence the expression of SEMA3C. Cell proliferation and migration were measured using CCK-8 and Transwell assays, respectively. Transfection with SEMA3C siRNA significantly downregulated the expression of SEMA3C in MCF-7 cells, and significantly suppressed cell proliferation and migration. Therefore, SEMA3C-targeted siRNA may be of potential use for the early diagnosis and treatment of breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.